Victory Capital Management Inc. Decreases Stake in Boston Scientific Corporation $BSX

Victory Capital Management Inc. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 38.7% in the third quarter, Holdings Channel reports. The institutional investor owned 483,268 shares of the medical equipment provider’s stock after selling 305,210 shares during the quarter. Victory Capital Management Inc.’s holdings in Boston Scientific were worth $47,181,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steph & Co. bought a new stake in Boston Scientific during the third quarter valued at $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter valued at about $26,000. Finally, United Community Bank raised its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BSX. Stifel Nicolaus cut their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Weiss Ratings downgraded Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Truist Financial dropped their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Mizuho cut their price target on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Barclays reduced their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $108.36.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Down 2.4%

Shares of Boston Scientific stock opened at $71.24 on Friday. The stock has a market capitalization of $105.71 billion, a P/E ratio of 36.72, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. The company has a 50-day simple moving average of $85.03 and a 200 day simple moving average of $94.55. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12-month low of $70.75 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the business posted $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.